MARKET

EVFM

EVFM

Evofem
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7621
-0.0202
-2.58%
Closed 19:13 09/21 EDT
OPEN
0.8000
PREV CLOSE
0.7823
HIGH
0.8040
LOW
0.7501
VOLUME
2.37M
TURNOVER
--
52 WEEK HIGH
5.53
52 WEEK LOW
0.6543
MARKET CAP
118.28M
P/E (TTM)
-0.4487
1D
5D
1M
3M
1Y
5Y
Seven Abstracts to be Presented on Evofem Biosciences' Vaginal pH Modulator
/PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that seven data sets from clinical trials of Phexxi® (lactic acid, citric acid and potassium bitartrate) and EVO100 will be presented at four medical society meetings in .
PR Newswire - PRF · 5d ago
'Schitt's Creek' Star Annie Murphy Headlines New Campaign For Phexxi Contraceptive
Evofem Biosciences, Inc. (NASDAQ: EVFM) has recruited Emmy Award-winning “Schitt’s Creek” actress Annie Murphy to star in a new marketing campaign for its Phexxi hormone-free contraceptive.
Benzinga · 09/09 14:52
Emmy® Award Winner Annie Murphy Partners with Evofem Biosciences to Talk Sex, Contraception, and Why She Chose Phexxi®
/PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced their partnership with Emmy® Award-winning actress to launch "House Rules," a national campaign to generate awareness of Evofem's hormone-free contraceptive, Phexxi, while also highli...
PR Newswire - PRF · 09/09 12:00
Evofem Biosciences (NASDAQ:EVFM) shareholders have endured a 78% loss from investing in the stock three years ago
Every investor on earth makes bad calls sometimes. But you want to avoid the really big losses like the plague. So...
Simply Wall St. · 09/02 13:03
Evofem Biosciences to Participate in Investor Conferences
Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that Chief Executive Officer Saundra Pelletier will present and host one-on-one meetings at two upcoming investor conferences as follows:
PR Newswire · 09/01 12:00
BRIEF-Evofem Biosciences Inc Says It May Consider Available Options To Regain Compliance With Nasdaq Bid Price Requirement
reuters.com · 08/27 10:12
Evofem Biosciences Receives Deficiency Letter From Nasdaq
MT Newswires · 08/27 07:16
First Wilshire Securities Management Inc Buys Vistra Corp, Antares Pharma Inc, Silicom, Sells ...
GuruFocus News · 08/24 22:38
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EVFM. Analyze the recent business situations of Evofem through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EVFM stock price target is 3.500 with a high estimate of 5.00 and a low estimate of 1.000.
EPS
Institutional Holdings
Institutions: 166
Institutional Holdings: 58.04M
% Owned: 37.40%
Shares Outstanding: 155.21M
TypeInstitutionsShares
Increased
21
16.16M
New
16
2.65M
Decreased
24
6.69M
Sold Out
38
18.51M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.40%
Pharmaceuticals & Medical Research
+0.74%
Key Executives
Non-Executive Chairman/Independent Director
William Hall
President/Chief Executive Officer/Director
Saundra Pelletier
Chief Financial Officer
Justin File
Executive Vice President/General Counsel/Secretary
Alexander Fitzpatrick
Other
Russell Barrans
Other
Kelly Culwell
Independent Director
Gillian Greer
Independent Director
Kim Kamdar
Independent Director
Tony O'Brien
Independent Director
Lisa Rarick
Independent Director
Colin Rutherford
No Data
  • All
  • Financials
  • Insiders
More
About EVFM
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and commercializing products to address needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from sexually transmitted infections (STIs). The Company's product, Phexxi vaginal gel, is an on-demand prescription contraceptive gel for women. Its pipeline product candidate, EVO100 vaginal gel, is evaluated for the prevention of chlamydia trachomatis infection and Neisseria gonorrhoeae in women. The Company also focuses on the development of EVO200 vaginal gel, its candidate for the reduction of recurrent bacterial vaginosis (BV).Its subsidiaries include Evofem Biosciences Operations Inc, Evofem Inc and Evofem Ltd.

Webull offers kinds of Evofem Biosciences Inc stock information, including NASDAQ:EVFM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EVFM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EVFM stock methods without spending real money on the virtual paper trading platform.